Jazz to buy Actio Biosciences for $820 million upfront, up to $500 million more in milestones
JAZZ•Jazz to acquire Actio Biosciences
Jazz Pharmaceuticals agreed to buy privately held Actio Biosciences for $820 million upfront, with up to $500 million tied to milestones.
The deal adds ABS-1230, a clinical-stage KCNT1 ion channel inhibitor for KCNT1+ epilepsy, a rare condition with no FDA-approved therapies.
Transaction structure and closing timing
Actio will spin out a new private company at closing, leaving ABS-1230 with the acquired business; Jazz will take a minority stake.
The transaction is expected to close in Q4 2026 and will be funded with cash on hand and existing financing facilities.
